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RESEARCH ARTICLE Open Access
Overexpression of MIG-6 in the cartilage
induces an osteoarthritis-like phenotype in
mice
Melina Bellini1,2, Michael A. Pest1,2, Manuela Miranda-Rodrigues1,2,3, Ling Qin4, Jae-Wook Jeong5 and Frank Beier1,2,3*
Abstract
Background: Osteoarthritis (OA) is the most common form of arthritis and characterized by degeneration of the
articular cartilage. Mitogen-inducible gene 6 (Mig-6) has been identified as a negative regulator of the epidermal
growth factor receptor (EGFR). Cartilage-specific Mig-6 knockout (KO) mice display increased EGFR signaling, an
anabolic buildup of the articular cartilage, and formation of chondro-osseous nodules. Since our understanding of
the EGFR/Mig-6 network in the cartilage remains incomplete, we characterized mice with cartilage-specific
overexpression of Mig-6 in this study.
Methods: Utilizing knee joints from cartilage-specific Mig-6-overexpressing (Mig-6over/over) mice (at multiple time
points), we evaluated the articular cartilage using histology, immunohistochemical staining, and semi-quantitative
histopathological scoring (OARSI) at multiple ages. MicroCT analysis was employed to examine skeletal
morphometry, body composition, and bone mineral density.
Results: Our data show that cartilage-specific Mig-6 overexpression did not cause any major developmental
abnormalities in the articular cartilage, although Mig-6over/over mice have slightly shorter long bones compared to
the control group. Moreover, there was no significant difference in bone mineral density and body composition in
any of the groups. However, our results indicate that Mig-6over/over male mice show accelerated cartilage
degeneration at 12 and 18 months of age. Immunohistochemistry for SOX9 demonstrated that the number of
positively stained cells in Mig-6over/over mice was decreased relative to controls. Immunostaining for MMP13
appeared increased in areas of cartilage degeneration in Mig-6over/over mice. Moreover, staining for phospho-EGFR
(Tyr-1173) and lubricin (PRG4) was decreased in the articular cartilage of Mig-6over/over mice.
Conclusion: Overexpression of Mig-6 in the articular cartilage causes no major developmental phenotype; however,
these mice develop earlier OA during aging. These data demonstrate that Mig-6/EGFR pathways are critical for joint
homeostasis and might present a promising therapeutic target for OA.
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Introduction
Osteoarthritis (OA), a chronic degenerative joint disease, is
the most common form of arthritis. OA affects 242 million
individuals worldwide, but that number will grow due to in-
creasing life expectancies [1]. This statistic is alarming, con-
sidering the disability, the loss of quality of life, and the
costs to the health system generated by OA. Currently,
there are pharmacological treatments available to manage
OA symptoms such as pain [2–4] as well as surgical joint
replacement at the end stage of disease [5, 6]. Unfortunately,
however, there is no cure for OA. Progressive understand-
ing of the pathophysiology of OA suggests that the disease
is a heterogeneous condition, so further research is needed
to direct the clinical approaches to disease management [7].
Recent studies have shown that OA is a multifactorial
disease of the whole joint; however, its pathogenesis re-
mains still poorly understood [8]. Genetic, environmen-
tal, and biomechanical factors can accelerate the onset
of OA [9]. The articular cartilage is a highly specialized
tissue that forms the smooth gliding surface of synovial
joints, with chondrocytes as the only cellular component
of the cartilage [10]. The homeostasis of the cartilage
extracellular matrix (ECM) involves a dynamic equilib-
rium between anabolic and catabolic pathways con-
trolled by chondrocytes [11]. The progression of OA is
associated with dramatic alteration in the integrity of the
cartilage ECM network formed by a large number of
proteoglycans (mostly aggrecan), collagen II, and other
non-collagenous matrix proteins [12]. In addition, ECM syn-
thesis is regulated by a number of transcriptional regulators
involved in chondrogenesis, specifically sex-determining-
region-Y box 9 (SOX9), L-SOX 5, and SOX6 that regulate
type II collagen (Col2a1) and aggrecan (Acan) gene expres-
sion [13]. On the other hand, catabolic events are dominant
in OA, and cells are exposed to degenerative enzymes such
as aggrecanases (e.g., ADAMTS-4, ADAMTS-5) [12, 14],
collagenases (e.g., MMP-1, MMP-3, MMP-8, MMP-13)
[15], and gelatinases (e.g.,MMP-2 and MMP-9), all of which
have implications in articular cartilage degeneration [16]. A
number of growth factors [17] play a role in OA pathology,
such as transforming growth factor-β [18], BMP-2 [19],
insulin growth factor 1 (IGF-1) [20], and fibroblast growth
factor (FGF), but the exact regulation of chondrocyte physi-
ology is still not completely understood.
Recent studies in our laboratory [21, 22] have identi-
fied the epidermal growth factor receptor (EGFR) and its
ligand transforming growth factor alpha (TGFα) as pos-
sible mediators of cartilage degeneration [23–25]. The
human TGFA gene locus was also strongly linked to hip
OA and cartilage thickness in genome-wide association
studies [26, 27]. TGFα stimulates EGFR signaling and
activates various cell-signaling pathways in chondro-
cytes, including extracellular signal-regulated kinase 1
and 2 (ERK1/2) and phosphoinositide 3-kinase (P13K)
[28]. EGFR signaling plays important roles in endochon-
dral ossification [29, 30], growth plate development [29],
and cartilage maintenance and homeostasis [31–33], but
many aspects of its action in the cartilage are still not
well understood. However, both protective and catabolic
effects of EGFR signaling in OA have been reported,
suggesting context-specific roles of this pathway [34].
Mitogen-inducible gene 6 (Mig-6) is also known as
Gene 33, ErbB receptor feedback inhibitor 1 (ERRFI1),
or RALT and is found in the cytosol [35]. Mig-6 protein
binds to and inhibits EGFR signaling through a two-
tiered mechanism: suppression of EGFR catalytic activity
and receptor downregulation [36]. Interestingly, various
studies have reported that loss of Mig-6 induces the
onset of OA-like symptoms in mice [35, 37–39].
Cartilage-specific (Col2-Cre) knockout of Mig-6 mice
results in the formation of chondro-osseous nodules in
the knee, but also increased thickness of the articular
cartilage in the knee, ankle, and elbow [40]. Prx1-Cre-
mediated knockout of Mig-6 in the limb mesenchyme
results in a similar phenotype as that observed in
cartilage-specific knockout mice [32]. These phenotypes
appeared to be caused by an increase in chondrocyte
proliferation in articular cartilage, supported by the in-
creased expression of Sox9 and EGFR activation in the
cartilage [32]. Since our studies suggest dosage- and/or
context-specific roles of EGFR signaling in the process
of cartilage degeneration in OA, in this study, we used a
cartilage-specific (Col2-Cre) to examine effects of Mig-6
overexpression specifically in articular cartilage. We
hypothesized that overexpression of Mig-6/EGFR accel-
erates cartilage degeneration during aging.
Materials and methods
Generation of Mig-6 overexpression mice
Mig-6 overexpression animals on a mixed C57Bl/6 and
agouti mouse background, with the overexpression cas-
sette in the Rosa26 locus [41], and bred for 10 generations
into a C57Bl/6 background were used. Transcription of
Mig-6 is under the control of a ubiquitously expressed
chicken beta actin-cytomegalovirus hybrid (CAGGS) pro-
moter but blocked by a “Stop Cassette” flanked by LoxP
sites (LSL) [41]. Mig-6 overexpression mice were bred to
mice carrying the Cre recombinase gene under the control
of the Collagen 2 promoter [42], to induce recombination
and removal of the Stop Cassette specifically in the cartil-
age. Throughout the manuscript, animals for homozygote
overexpression of Mig-6 from both alleles are termed
Mig-6over/over (Mig-6over/overCol2a1-Cre+/−), while control
mice are identical but without the Cre gene (noted as
“control” in this manuscript for simplicity). Mice were
group-housed (at least one pair of littermate-matched
control and overexpression animals), on a standard 12-h
light/dark cycle, without access to running wheels and
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with free access to mouse chow and water. Animals were
weighed prior to euthanasia by asphyxiation with CO2. All
animal experiments were done in accordance with the
Animal Use Subcommittee at the University of Western
Ontario and conducted in accordance with the guidelines
from the Canadian Council on Animal Care.
Genotyping
Genotype was determined by polymerase chain reaction
(PCR) analysis using DNA processed from biopsy sam-
ples of ear tissue from mice surviving to at least 21 days
of age. PCR strategy: primer set P1 and P2 can amplify a
300-bp fragment from the wild-type allele, whereas P1
and P3 can amplify a 450-bp fragment from the targeted
ROSA26 locus allele [41] (Supplementary Figure/
Table 1).
RNA isolation and quantitative real-time PCR
Total RNA was isolated from postnatal day 0 (P0) mouse
cartilage of Mig-6over/over and control littermates using
TRIzol® (Invitrogen) as per the manufacturer’s instructions
and as previously described [43]. Complementary DNA
(cDNA) was synthesized using the iScript cDNA Synthesis
kit (Bio-Rad) with 1 μg of RNA (Bio-Rad Laboratories)
and combined with 300 nM of forward and reverse
primers (for primer sequences, please see Supplementary
Figure 1E) as well as iQ™ SYBR® Green Supermix (Bio-Rad
Laboratories) for PCR on a Bio-Rad CFX384 RT-PCR
system. Relative gene expression was normalized to the in-
ternal control glyceraldehyde 3-phosphate dehydrogenase
(Gapdh), calculated using the ΔΔCT method.
Histopathology of the knee
The limbs from Mig-6over/over and control mice were har-
vested and fixed in 4% paraformaldehyde (Sigma) for 24
h and decalcified in ethylenediaminetetraacetic acid (5%
EDTA in phosphate-buffered saline (PBS), pH 7.0. The
joints were processed and embedded in paraffin in sagit-
tal or frontal orientation, with the serial sections taken
at a thickness of 5 μm. Sections were stained with tolui-
dine blue (0.04% toluidine blue in 0.2M acetate buffer,
pH 4.0, for 10 min) for glycosaminoglycan content and
general evaluation of the articular cartilage. All images
were taken with a Leica DFC295 digital camera and a
Leica DM1000 microscope.
Thickness of proximal tibia growth plate
For early developmental time points such as newborn
(P0), the sagittal knee sections stained with toluidine blue
were used to measure the width of the zones of the epi-
physeal growth plate in the proximal tibia. The average
thickness of the resting and proliferative zones combined
was evaluated by taking three separate measurements at
approximately equal intervals across the width of the
growth plate. The average hypertrophic zone thickness
was also measured using 3 different measurements across
the width of the growth plate, starting each measurement
at the border of the proliferative and hypertrophic zones
and ending at the subchondral bone interface. The third
average measurement was then taken for the thickness of
the entire growth plate. The ImageJ software (v.1.51) [44]
was used for all measures, with the observer blinded to
the genotype.
Articular cartilage evaluation
Articular cartilage thickness was measured from tolui-
dine blue-stained frontal sections by a blinded observer.
Articular cartilage thickness was measured separately for
the non-calcified articular cartilage (measured from the
superficial tangential zone to the tidemark), and the cal-
cified articular cartilage (measured from the subchondral
bone to the tidemark) across three evenly spaced points
from all four quadrants of the joint (medial/lateral tibia
and femur) in 4 sections spanning at least 500 μm. The
ImageJ software (v.1.51) [44] was used to measure the
thickness of the articular cartilage.
Micro-computerized tomography (μCT)
Whole-body scans were collected in 6-week-, 11-week-,
12-month-, and 18-month-old control and Mig-6over/over
male and female mice. Mice were euthanized and im-
aged using the General Electric (GE) SpeCZT microCT
machine [45] at a resolution of 50 μm/voxel or 100 μm/
voxel. GE Healthcare MicroView software (v2.2) was
used to generate 2D maximum intensity projection and
3D isosurface images to evaluate skeletal morphology.
MicroView was used to create a line measurement tool
in order to calculate the bone lengths; femur lengths
were calculated from the proximal point of the greater
trochanter to the base of the lateral femoral condyle.
Tibia lengths were measured from the midpoint medial
plateau to the medial malleolus. Humerus lengths were
measured from the midpoint of the greater tubercle to
the center of the olecranon fossa.
Body composition analysis
MicroView software (GE Healthcare Biosciences) was
used to analyze the microCT scans at the resolution of
100um/voxel. Briefly, the region of interest (ROI) was
used to calculate the mean of air, water, and an epoxy-
based, cortical bone-mimicking calibrator (SB3; Gammex,
Middleton, WI, USA) (1100mg/cm3) [46]. A different set
of global thresholds was applied to measure adipose, lean,
and skeletal mass (− 275, − 40, and 280 Hounsfield units
(HU), respectively). Moreover, bone mineral density
(BMD) was acquired as the ratio of the average HU (from
the value of the skeletal region of interest) in order to
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calculate the HU value of the SB3 calibrator, multiplied by
the known density of the SB3 as described [45].
OARSI histopathology scoring
Serial sections through the entire knee joint were scored
according to the OARSI histopathology scoring system
[47] by two blinded observers on the four quadrants of the
knee: lateral femoral condyle (LFC), lateral tibial plateau
(LTP), medial femoral condyle (MFC), and medial tibial
plateau (MTP). Histologic scoring from 0 to 6 represent
the OA severity, from 0 (healthy cartilage) to 6 (erosion of
more than 75% of the articular cartilage). Individual scores
are averaged first for each observer, then across observers,
and OA severity is shown as described for each graph.
Scores were compared between male and female Mig-
6over/over and control mice at both 12 and 18months of
age. All images were taken with a Leica DFC295 digital
camera and a Leica DM1000 microscope.
Immunohistochemistry
Frontal paraffin sections of knees were used for immuno-
histochemical analysis, with slides with “no primary anti-
body” as a control. All sections were deparaffinized and
rehydrated as previously described [40, 48]. Subsequently,
the sections were incubated in 3% H2O2 in methanol for
15min to inhibit endogenous peroxidase activity. After
rinsing with water, 5% goat or donkey serum in PBS was
applied to reduce non-specific background staining. The
sections were incubated overnight at 4 °C with primary
antibodies against SOX9 (R&D Systems, AF3075), MMP13
(Protein Tech, Chicago, IL, USA, 18165-1-AP), lubricin
(Abcam, ab28484) (primary concentration antibody for all
three 1:100), and phospho-EGFR (phosphoTyr-1173; Cell
Signaling Technology) (primary concentration antibody 1:
50). After washing, the sections were incubated with horse-
radish peroxidase (HRP)-conjugated donkey anti-goat or
goat anti-rabbit secondary antibody (R&D System and
Santa Cruz, secondary concentration antibody 1:200),
before incubation with diaminobenzidine substrate as a
chromogen (Dako, Canada). Finally, the sections were
counterstained with 0.5% methyl green (Sigma) and
mounted. Cell density of articular cartilage chondrocytes
from 6- and 11-week-old male mice was determined by
counting all lacunae with evidence of nuclear staining in
the lateral and medial femur/tibia using a centered region
of interest measuring 200 μm wide and 70 μm deep from
the articular surface by a blinded observer. For newborn
(P0) animals, the region of interest was measured 200 μm
wide and 100 μm deep from the proliferative zone.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism (v6.0). Differences between the two groups were
evaluated using Student’s t test, and two-way ANOVA
was used to compare the 4 groups followed by a Bonfer-
roni multiple comparisons test. All n values represent
the number of cartilage-specific Mig-6-overexpressing
mice and control littermates used in each group.
Results
Increased MIG-6 mRNA from overexpression of Mig-6
mice and decreased EGFR staining
We bred mice for conditional overexpression of Mig-6
[41] to mice expressing Cre recombinase under the con-
trol of the collagen II promoter. Homozygote mice over-
expressed Mig-6 in all collagen II-producing cells (and
their progeny) from both Rosa26 alleles and are referred
to as Mig-6over/over from here on. Control mice do not ex-
press Cre. Genomic DNA was extracted from ear notches
to identify homozygous mice Mig-6over/overusing standard
PCR analysis. Overexpressing mice were obtained at the
expected Mendelian ratios (data not shown). Real-time
RT-PCR revealed increased levels of Mig-6 expression in
the cartilage of Mig-6over/over mice from postnatal day 0
(PO) (Fig. 1a). Since Mig-6 negatively regulates EGFR sig-
naling [31, 32, 40], immunohistochemistry was performed
for phospho-EGFR (Tyr-1173) (pEGFR), with no primary
antibody controls. Frontal knee sections from 11-week-old
male Mig-6over/over mice showed decreased pEGFR staining
in the medial compartment in the knee joint (Fig. 1b–e),
as expected upon Mig-6 overexpression.
Overexpression of Mig-6 has minor effects on skeletal
phenotypes during development
Male mutant gained weight at the same rate as controls
over the examined 10-week period, while female Mig-
6over/over mice were slightly lighter than controls starting
at 8 weeks of age (Suppl. Fig. 2A-B). These differences
persisted at 12 months of age for female mice, while at
18 months, both male and female mutant mice were
lighter than their controls (Suppl. Fig. 2C-D). Growth
plates of postnatal day 0 (P0) Mig-6over/over and control
mice were analyzed by histology. No major differences
in the tibia growth plate architecture were seen between
genotypes (Suppl. Fig. 3A). While the length of the total
growth plate was slightly reduced in Mig-6over/over mice,
differences in lengths of either the combined resting/
proliferative or hypertrophic zones were not statistically
significant (Suppl. Fig. 3B-D).
Mice overexpressing Mig-6 have shorter long bones than
control mice
Skeletal morphology and bone length were examined by
microCT mice at the ages of 6 weeks and 12 and 18
months. Scans of Mig-6over/over male and female mice
and their controls were used to generate 3D isosurface
reconstructions of 100 μm/voxel μCT scans, in order to
measure long bone lengths (femurs, humeri, and tibiae)
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in GE MicroView v2.2 software. Mutant bones were
slightly shorter throughout life, with the exception of the
male humeri at 12 months that did not show any statisti-
cally significant difference (Fig. 2a–d). In contrast, male
mice did not show any differences in bone mineral dens-
ity at 11 weeks, 12 months, or 18 months, compared to
controls (Suppl. Fig. 4A-C). In addition, no differences
in body mass composition were seen in male mutant
and control mice at 11 weeks, 12 months, and 18months
of age (Suppl. Fig. 5A1-C2).
Mig-6-overexpressing mice have healthy articular
cartilage during skeletal maturity
We next examined articular cartilage morphology in 11-
week-old mutant and control mice using toluidine blue-
stained paraffin frontal knee sections (Fig. 3a, b). The
average thickness of the calcified articular cartilage and
non-calcified articular cartilage in the lateral femoral
condyle (LFC), lateral tibial plateau (LTP), medial fem-
oral condyle (MFC), and medial tibial plateau (MTP)
from control and Mig-6over/over male (Fig. 3c, d) and fe-
male (Suppl. Fig. 6A-D) mice did not show statistically
significant differences. Histological analyses of the knee
sections from male and female mice did not show any
loss of proteoglycan, fibrillation, or erosion in the articu-
lar cartilage of mutant mice.
Overexpression of Mig-6 in the cartilage induces an
osteoarthritis-like phenotype in mice during aging
Since aging is a primary risk factor in OA [49], we next ex-
amined the knee joints in 12- and 18-month-old control
and Mig-6over/over mice. Toluidine blue-stained sections were
evaluated by two blinded observers, using OARSI recom-
mendations [47]. At 12months of age, male control mice
showed minor signs of cartilage damage, such as loss of pro-
teoglycan staining, but no significant structural degeneration
Fig. 1 Mig-6 mRNA and EGFR protein expression in the articular cartilage of cartilage-specific Mig-6-overexpressing mice. a Levels of Mig-6 mRNA
determined by qRT-PCR analysis on P0 epiphysis. Individual data points presented with mean ± SEM (P < 0.05). Data analyzed by two-tailed
Student t tests from 11 mice per group. b Immunostaining of phosphorylated epidermal growth factor receptor (pEGFR; Tyr-1173) in the knee
joints of 11-week-old control and c Mig-6over/over (Mig-6over/overCol2a1-Cre+/−) is decreased in response to increased Mig-6 levels. Frontal sections of
mouse articular cartilage incubated without primary antibody, as a negative control, exhibited no staining (d). Cartilage-specific Mig-6 KO mice
served as a positive control (e). N = 5 mice/genotyping. MFC, medial femoral condyle; MTP, medial tibial plateau. Scale bar = 100 μm
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(Fig. 4a). However, seven of nine Mig-6over/over male mice
showed more extensive cartilage damage in their medial side
(erosion to the calcified layer lesion for 25 to 50% of the
medial quadrant) (Fig. 4b). OARSI scoring confirmed in-
creased OA-like damage in mutant mice (Fig. 4c). Similarly,
at 18months of age, the male control group showed min-
imal cartilage degeneration in 3 of 6 mice (Suppl. Fig. 7A-B).
Mig-6over/over male mice showed more severe cartilage ero-
sion in the medial tibial plateau in 3/6 animals. This result
was again supported by significantly increased OARSI cartil-
age damage scores (Suppl. Fig. 7C). Moreover, for the female
group at 12months, control mice did not show cartilage
damage. However, Mig-6over/over female mice showed signs
of OA-like cartilage damage in 3/8 animals (Suppl. Fig. 8A-
C). In addition, at 18months of age, female control mice
showed healthy cartilage, and 3/8 Mig-6over/over female mice
showed some proteoglycan loss and cartilage degeneration
on the medial side (Suppl. Fig. 9A-C).
Overexpression of Mig-6 decreases Sox9 expression
During chondrogenesis, the transcription factor SOX9 is
required for cartilage formation and normal expression
of collagen and aggrecan [50]. The sagittal and frontal
sections of paraffin-embedded knees from postnatal day
0 (P0), 6-week-old, 11-week-old, 12-month, and 18-
month-old male mice were used for SOX9 immuno-
staining. At P0, nuclear SOX9 expression was observed
in the resting and proliferative zone of the growth plate
in both genotypes (Fig. 5a, b). Cell density was not dif-
ferent between genotypes (Fig. 5c). In control mice, 78%
of chondrocytes were positive for SOX 9 immunostain-
ing, while the proportion of positive cells was only 53%
in Mig-6over/over mice (Fig. 5d). At 6 weeks old, the total
cell number in control male and Mig-6over/over mice is
similar (Fig. 5g), but the percentage of SOX9-positive
cells was decreased in mutant mice (Fig. 5h). A similar
phenotype was present at 11 weeks (Suppl. Fig. 10A-B).
At 12 months of age, SOX9 is present more in the lateral
side (LTP and LFC) than the medial side (MTP and
MFC) in both strains, with a few positive cells present in
the medial side of the control strain. On the other hand,
Mig-6over/over mice showed fewer SOX9-positive cells on
the medial side due to the articular cartilage damage
(Suppl. Fig. 11A-B). Similar results were found at 18
Fig. 2 Long bones of Mig-6-overexpressing mice are significantly shorter than those of control long bone during growth and aging. The lengths
of the right humeri, tibiae, and femora were measured on microCT scans of mice at different ages using GE MicroView software. a 6-week-old
male and female control and Mig-6-overexpressing mice. b Eleven-week-old male and female control and Mig-6-overexpressing mice. c Twelve-
month-old male and female control and Mig-6-overexpressing mice. d Eighteen-month-old male and female control and Mig-6-overexpressing
mice. (A1) Representative 3D isosurface reconstructions of 100 μm/voxel μCT scans. There were statistically significant differences between control
and Mig-6over/over male and female groups. Individual data points presented with mean ± SEM (P < 0.05). Data analyzed by two-tailed Student t
tests from 6 to 12 mice per group (age/gender)
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months of age in Mig-6over/over, with decreased SOX9 im-
munostaining in their medial side compared to the con-
trol (data not shown). For all ages, negative controls did
not show staining in chondrocytes.
Overexpression of Mig-6 decreases expression of lubricin
Lubricin (aka PRG4/superficial zone protein) is a proteogly-
can that plays an important role as a lubricant in the joint
[51]. EGFR signaling is crucial for the cartilage lubrication
function and regulates the induction of Prg4 expression
which is necessary for smooth movement [31, 32]. Immu-
nohistochemistry for lubricin in 11-week-old (Fig. 6a–d)
and at 12-month-old animals demonstrated less staining in
the superficial zone of the medial side of Mig-6over/over mice
than in the control group (Suppl. Fig. 12A-B).
MMP13 immunostaining in Mig-6-overexpressing and
control mice
Matrix metalloproteinase (MMP13) is highly expressed
in OA [52, 53]. The frontal sections of the knees from
12- and 18-month-old control and Mig-6over/over male
mice were used for MMP13 immunohistochemistry. At
12months, pericellular staining was observed in the lateral
articular cartilage of male mice from both genotypes, along
with the expected subchondral bone staining (Suppl.
Fig. 13A-B). Less staining was observed on the medial side
of control mice while advanced cartilage degeneration in
mutant mice precluded staining. Negative controls did not
show staining in the cartilage or subchondral bone. The ar-
ticular cartilage from 18-month-old mice showed similar
staining patterns and intensity of MMP13 immunostaining
in the lateral side of both genotypes; however, in the medial
side of Mig-6over/over mice, MMP13 staining is seen on the
cartilage surface (lesion sites) and also observed in the sub-
chondral bone (data not shown).
Discussion
The maintenance of articular cartilage homeostasis relies
on a dynamic equilibrium involving growth factors [54],
genetics [55], mechanical forces [56], obesity, and injury
that all play a role in the onset of osteoarthritis [57]. A
better understanding of the underlying molecular mech-
anism is required to design therapies for preventing the
progression of OA. Recent studies from our laboratory
Fig. 3 Articular cartilage from 11-week-old Mig-6over/over male mice appeared healthy at skeletal maturity. Representative (n= 5/group, toluidine blue)
stained frontal sections of the knee joints from 11-week-old control (a) and Mig-6over/over (b) mice. Mig-6-overexpressing mice show similar articular cartilage
thickness when compared to controls at 11weeks of age. The average thickness of the calcified articular cartilage (c) and non-calcified articular cartilage (d)
in the lateral femoral condyle (LFC), lateral tibial plateau (LTP), medial femoral condyle (MFC), and medial tibial plateau (MTP) was measured. Individual data
points presented with mean ± SEM. Data analyzed by two-way ANOVA (95% CI) with Bonferroni post hoc test. Scale bar = 100 μm
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and others have identified the epidermal growth fac-
tor receptor (EGFR) and Mig-6 as possible mediators
of articular cartilage homeostasis [31, 33, 34, 40].
Mig-6 is a cytosolic protein and negative feedback
regulator of EGFR signaling [58]; thus, Mig-6 can be
a potential tumor suppressor [41, 59–62]. In addition,
whole-body knockout of the Mig-6 gene in mice re-
sults in degenerative joint disease [37]. We also have
shown previously that constitutive cartilage-specific
deletion of Mig-6 (Mig-6 KO) results in increased ar-
ticular cartilage thickness and cell density in the
joints of 12-week-old mice [40]. Cartilage-specific
Mig-6 KO mice show the same anabolic effect in the
joint cartilage at 21 months of age (unpublished).
Previous research demonstrates that Mig-6 overex-
pression acts as a negative feedback regulator of EGFR-
ERK signaling [41]; however, these studies did not yet
analyze joint tissues. Since our studies suggest dosage-
and/or context-specific roles of EGFR signaling in joint
homeostasis and OA [34], we now examined whether
overexpression of Mig-6 alters these processes. Here, we
report that cartilage-specific constitutive overexpression
of Mig-6 did not cause cartilage degeneration in young
mice, but early-onset OA in middle-aged mice. While
we observed some effects of Mig-6 overexpression on
bone length and weight, these effects were subtle and
not accompanied by major morphological or histological
changes in the growth plate cartilage, overall skeletal
Fig. 4 Twelve-month-old Mig-6over/over male mice develop OA-like cartilage degeneration. Toluidine blue-stained sections of the knee joints from 12-
month male control (a) and Mig-6over/over (b) mice were evaluated for cartilage damage following the OARSI histopathological scale on two quadrants
of the knee: MFC, medial femoral condyle; MTP, medial tibial plateau. OARSI-based cartilage degeneration scores are significantly higher in the MFC
and MTP of Mig-6-overexpressing mice, corresponding to the increased damage observed histologically (c). Data analyzed by two-way ANOVA with
Bonferroni’s multiple comparisons test. Individual data points presented with mean ± SEM. All scale bars= 100 μm. N = 9 mice/group
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morphology, or body composition. A previous study
showed that the deletion of EGFR in bone tissue (Col1-
Cre EgfrWa5/f) resulted in shorter femurs compared to
wild-type mice [63], consistent with our findings. The
EGFR network is essential during long bone develop-
ment, since previous studies have shown that EGFR- or
TGFα-deficient mice exhibit a widened zone of hyper-
trophic chondrocytes [23, 64]. Moreover, Qin and
colleagues have shown that the administration of the
EGFR inhibitor, gefitinib, into 1-month-old rats results
in an enlarged hypertrophic zone due downregulation of
MMP-9, MMP-13, and MMP-14 [30]. Together, these
data suggest a critical role of EGFR during endochondral
ossification and elucidate the downstream mechanism of
EGFR [65]. Further research is required to provide more
evidence of EGFR/Mig-6over/over signaling during bone
formation, but many of these effects are relatively subtle
and transient, and likely unrelated to the much more
severe phenotypes observed later. Histologically, our
findings showed that mice with cartilage-specific Mig-6
overexpression showed healthy articular cartilage with
no significant difference in articular cartilage thickness
Fig. 5 SOX9 immunostaining shows a decrease in positive cells in Mig-6-overexpressing mice at p0 and 6 weeks. Immunostaining of SOX9 in the
knee joints of control (a/e) and Mig-6over/over (Mig-6over/overCol2a1-Cre+/−) (b/f) mice. Total cell number/area from control and Mig-6over/over mice (c/
g). Percentage of Sox9-positive cells from control and Mig-6over/over at p0 and 6 weeks (d/h). Data analyzed by two-tailed Student t tests from 5
mice per group. Individual data points presented with mean ± SEM (P < 0.05). Scale bar = 100 μm and 50 μm
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from the control group at the ages of 6 weeks and 11
weeks. However, Mig-6over/over mice developed severe de-
generation of the articular cartilage with aging. More
prevalent, the knee joints of Mig-6over/over male mice
showed significantly advanced cartilage degeneration.
The same pattern, but with more severe damage, was
seen in 18-month-old mice. As previously described, sex
hormones play a role in OA disease where male mice
develop more severe OA [66]. SOX9 is crucial in chon-
drogenesis during endochondral bone formation, articu-
lar cartilage development, and cartilage homeostasis
[50]. Previous in vivo models using cartilage (Col2)-Cre-
or limb mesenchyme (Prx1)-Cre-specific ablation of
Mig-6 showed increased expression of SOX9 in the
articular cartilage. Consistent with these data, we show
that the percentage of SOX9-positive chondrocytes was
decreased in the knee joints of 6- and 11-week-old male
Mig-6over/over mice compared to controls, despite the
absence of histological defects in articular cartilage. The
percentage of SOX9-expressing cells was also reduced in
Mig-6over/over mice at later ages. However, our previous
in vitro studies suggested that TGFα suppresses the
expression of anabolic genes such as Sox9, type II colla-
gen, and aggrecan in primary chondrocytes [21]. A po-
tential explanation for these conflicting results is the
context-specific role of EGFR signaling in the cartilage,
as discussed previously [34]; this pathway can both pro-
mote cartilage degeneration and confer protection of the
cartilage, depending on the context. Another potential
explanation is the difference between in vivo and in vitro
experiments. Our data from the current study suggest
that reduction in Sox9 expression precedes the degener-
ation of articular chondrocytes in our mutant mice. In
addition, we observed decreased expression of lubricin/
PRG4 in these joints, which might also contribute to the
observed joint pathologies. PRG4 has been shown to be
regulated by EGFR signaling before [31, 32], in support
of our findings. While the EGFR is the best character-
ized substrate of Mig-6, other substrates have been de-
scribed. Mig-6 binds to different proteins such as the
cell division control protein 42 homolog (Cdc42) [67],
proto-oncoprotein (c-Abl) [68], and the hepatocyte
growth factor receptor (c-Met) [69]. While we cannot
exclude that deregulation of these other substrates
Fig. 6 Lubricin immunostaining is slightly decreased in the articular cartilage of cartilage-specific Mig-6-overexpressing mice at 11 weeks of age.
Immunostaining of sections of the knee joint indicates the presence of lubricin (PRG4) in superficial zone chondrocytes. IHC reveals no staining
for the negative control (c). Sections from Mig-6 KO mice served as the positive control (d). N = 4–5 mice/genotyping. Scale bar = 100 μm
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contributes to the observed phenotypes, the similarities
of defects in our mice with those seen upon cartilage-
specific deletion of EGFR suggest that decreased EGFR
signaling is the main cause for the advanced OA observed
in our mutant mice. Nevertheless, it will be important to
determine whether signaling through cMet and other
pathways is altered as well.
Future studies will include an examination of Mig-6-
overexpressing mice in other models of OA, such as the
post-traumatic model of DMM (destabilization of the
medial meniscus) surgery. As discussed above, the role
of the EGFR/Mig-6 pathway in OA is context-specific.
Thus, we cannot extrapolate from our aging model to all
forms of OA. In addition, the role of Mig-6 in human
OA will require further studies. While there is plenty of
evidence for crucial roles of the EGFR pathway in hu-
man OA, and Mig-6 is a crucial regulator of this path-
way, more direct analyses of this role in human cartilage
are required [21, 70, 71].
Mig-6 expression is heavily regulated. While its expres-
sion in human OA has not been studied thoroughly, one
can easily imagine upregulation by a number of biochem-
ical (such as EGFR and other growth factors, as in other
tissues) or biomechanical factors. Mig-6 overexpression
has been demonstrated in OA cartilage in dogs [38], sug-
gesting that the same could occur in human OA. More
generally, the EGFR pathway, through which Mig-6 pri-
marily acts, has been shown to be deregulated in human
OA in several studies [21, 34, 71]. Thus, the current study
is highly relevant to the pathogenesis of human OA.
Conclusion
In conclusion, we show for the first time that cartilage-
specific Mig-6 overexpression in mice results in reduced
EGFR activity in chondrocytes, reduced SOX9 and
PRG4 expression, and accelerated development of OA.
These data highlight the important and context-specific
role of the EGFR-Mig-6 signaling pathway in joint
homeostasis and point towards potential targeting of this
pathway for OA therapy.
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